XDCs - From Discovery To Manufacuting, One Partner

Developing bioconjugates requires managing intricate chemistry and multi-step manufacturing, from early-stage discovery through clinical supply. Bringing these complex therapeutics to life demands expertise across a diverse range of modalities, including monoclonal antibodies, peptides, and oligonucleotides. Efficient advancement relies on robust discovery workflows capable of producing 5 to 500 mg scales , which then seamlessly transition into development scales up to 10 grams and manufacturing capacities reaching 1 kilogram.

A central challenge lies in optimizing payload and linker chemistry. Success hinges on designing stable cleavable or non-cleavable linkers paired with potent payloads, such as topoisomerase inhibitors and auristatins. Furthermore, utilizing advanced conjugation technologies—like site-specific or enzymatic methods —ensures the necessary precision for downstream efficacy.

To explore the full bioconjugation platform, specialized containment capabilities up to OEB 5 , and integrated analytical support, download the complete capability overview.